Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis - PubMed
3 hours ago
- #retinal diseases
- #pharmacovigilance
- #adverse drug reactions
- This study compared intraocular inflammation (IOI) associated with high-dose intravitreal anti-VEGF agents (brolucizumab, faricimab, and 8 mg aflibercept) using FDA Adverse Event Reporting System (FAERS) data.
- The strongest safety signals were: brolucizumab linked to retinal vasculitis (ROR=7,451.51), faricimab linked to vitritis (ROR=655.54), and 8 mg aflibercept linked to anterior chamber inflammation (ROR=1,749.13).
- IOI events were classified into four phenotypes: anterior chamber inflammation, vitritis, retinal vasculitis, and non-infectious endophthalmitis.
- Across all IOI phenotypes, signal strength followed a descending gradient: brolucizumab showed the strongest signals, followed by aflibercept 8 mg, then faricimab.
- The findings indicate significant differences in IOI profiles among high-dose anti-VEGF agents, emphasizing the need for individualized risk assessment in clinical decision-making.